CRB-701

Phase 3Small molecule

CCorbus Pharmaceuticals Inc.

CRB-701 is one of 52 small molecule programs targeting Oropharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharyngeal CarcinomaNot yet recruiting

Solid TumorsRecruiting

Oropharyngeal CarcinomaPhase 3

Not yet recruiting

Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

137 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

6 2

Lynparza

AstraZeneca

Phase 3

4 3

Lenvima

Eisai

Phase 3

3 4

Taxol

Teva

Phase 2

15 5

Gemzar

Johnson & Johnson

Phase 2

12 6

Opdivo

Bristol-Myers Squibb

Phase 2

10 7

Imfinzi

AstraZeneca

Phase 2

6 8

Beyfortus

BeiGene

Phase 2

5 9

Fludara

Sanofi

Phase 2

3 10

Camptosar

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Solid Tumors

NCT06265727

Q1 2029

Phase 3Not yet recruiting

Oropharyngeal Carcinoma

NCT07768189

Clinical

Trials by Indication[1]

Solid Tumors1 trial

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Recruiting·CCorbus Pharmaceuticals Inc.·Phase 1/2·NCT06265727·348 enrolled

Oropharyngeal Carcinoma1 trial

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

Not yet recruiting·CCorbus Pharmaceuticals Inc.·Phase 3·NCT07768189·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CRB-701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRB-701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRB-701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corbus Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCorbus Pharmaceuticals Inc.

CRB-701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Trials by Indication[1]

Solid Tumors1 trial

Oropharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News